Effect of glycyrrhizin on serum levels of PDGF, IL-17, MCP-1 and SRF in patients with glioma
- VernacularTitle:甘草酸对胶质瘤患者血清PDGF、IL-17、MCP-1及SRF血清反应因子的影响研究
- Author:
Gaofei GUO
;
Renfang WANG
;
Wei ZHANG
- Publication Type:Journal Article
- Keywords:
glycyrrhizin;
glioma;
platelet derived growth factor;
interleukin 17;
monocyte chemotactic protein 1;
serum response factor
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(9):94-96
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyse effect of glycyrrhizin on serum levels of platelet derived growth factor ( PDGF ) , interleukin 17 ( IL-17 ) , monocyte chemotactic protein 1 (MCP-1) and serum response factor (SRF) in patients with glioma.Methods 48 patients who were diagnosed with glioma in our hospital were collected.All patients were randomly divided into experimental group and control group,24 cases in each group.All patients were treated with surgery,control group was treated with temozolomid capsule(150 mg/m2 ) orally, one times per day, 28 days for a treatment period of 5 days continuous administration.On the basis of control group, experimental group was treated with compound ammonium glycyrrhetate injection 40 mL, dissolved in 250 mL 5% glucose solution intravenously,one times per day,four weeks was a period of treatment.After two groups were treated two period of treatment,the serum levels of PDGF, IL-17,MCP-1and SRF were detected in all patients.Results After treatment, compared with control group, the serum PDGF level was lower than that of experimental group (P<0.05);the serum IL-17 level was lower than that of experimental group (P<0.05);the serum MCP-1 level was higher than that of experimental group ( P <0.05 );the serum SRF level was lower than that of experimental group ( P <0.05).Conclusion Glycyrrhizin could significantly reduce the serum PDGF, IL-17 and SRF levels,increase MCP-1 levels, have guidance significance for clinic.
